New combo therapy shows promise for Hard-to-Treat breast cancer
NCT ID NCT02390427
First seen Apr 11, 2026 · Last updated May 24, 2026 · Updated 7 times
Summary
This study tested a new drug called taselisib, which blocks a protein that helps cancer grow, combined with standard HER2-targeted therapies in 68 people with advanced HER2+ breast cancer. The main goal was to find the safest dose for future studies. Researchers also looked at whether the combination could shrink tumors or slow the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
Conditions
Explore the condition pages connected to this study.